Could a lower chemo dose make transplants safer for older patients?
NCT ID NCT04959175
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a lower dose of the drug cyclophosphamide, given after a bone marrow transplant, can reduce side effects while still preventing the donor's immune cells from attacking the recipient's body (graft-versus-host disease). The trial includes adults aged 18-85 with blood cancers that haven't responded well to standard treatments. Participants receive a stem cell transplant along with chemotherapy and radiation, followed by the lower-dose cyclophosphamide, and are monitored for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclophosphamide
What this could lead to
If successful, this could make bone marrow transplants safer for older or frailer patients by reducing severe side effects from the standard chemotherapy dose.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 320 participants, so the lower dose may not prevent graft-versus-host disease as effectively, or side effects could still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••